Indian Journal of Gastroenterology

, Volume 29, Issue 2, pp 62–65 | Cite as

Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C

  • Ajit Sood
  • Praveen Sobti
  • Vandana Midha
  • Dinesh Singla
  • Amarjeet Kaur
  • Sandeep Kaushal
  • Neena Sood
  • Rasham Mittal
  • Sandeep Puri
Original Article



Treatment of HCV infection in patients with thalassemia major (TM) is limited by the lack of large clinical trials and concerns about ribavirin-induced hemolysis.


We conducted a prospective, randomized, open-label study to determine efficacy and tolerability of pegylated-interferon alfa 2b (1.5 μg/kg/week) alone (group A) or with ribavirin (12–15 mg/kg/day; group B) in patients with TM and chronic HCV infection. Patients with genotype 1 or 4 HCV were treated for 48 weeks and those with genotype 3 or 2 HCV for 24 weeks. Early viral response (EVR; after 12 weeks of treatment), end-of-treatment virological response (ETR) and sustained virological response (SVR; 6 months after stopping therapy) were assessed.


Of 40 patients, 20 each were allocated to the two treatment groups. EVR rates in group A and B were 15 (75%) and 18 (90%), respectively. ETR occurred in 17/20 (85%) patients in each group. SVR occurred in 8 (40%) patients in group A and 14 (70%) in group B. Blood transfusion requirements increased in one patient in group A and four patients in group B. One patient in group A had severe sepsis and one in group B had nephrotic syndrome. Two patients in each group required reduction in drug dose.


In patients with TM and chronic HCV infection, pegylated interferon alfa 2b and ribavirin combination therapy achieves a higher SVR rate than pegylated interferon alone, and is well tolerated except for an increase in blood transfusion requirement.


Blood transfusion hemolysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Angelucci E. Antibodies to hepatitis C virus in thalassemia. Haematologica 1994;79:353–355.PubMedGoogle Scholar
  2. 2.
    Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol 1990;43:638–640.CrossRefPubMedGoogle Scholar
  3. 3.
    Marwaha RK, Bansal D, Sharma S, et al. Seroprevalence of hepatitis C and B virus in multiply transfused beta-thalassemics: results from a thalassemic day care unit in north India. Vox Sang 2003;85:119–120.CrossRefPubMedGoogle Scholar
  4. 4.
    Jaiswal SP, Chitnis DS, Jain AK, Inamdar S, Porwal A, Jain SC. Prevalence of hepatitis viruses among multitransfused homogenous thalassaemia patients. Hepatol Res 2001;19:247–253.CrossRefPubMedGoogle Scholar
  5. 5.
    Agarwal MB, Malkan GH, Bhave AA, et al. Antibody to hepatitis-C virus in multi-transfused thalassaemics — Indian experience. J Assoc Physicians India 1993;41:195–197.PubMedGoogle Scholar
  6. 6.
    Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Di Marco V, Capra M, Gagliardotto F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008;93:1243–1246.CrossRefPubMedGoogle Scholar
  8. 8.
    Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187–1193.PubMedGoogle Scholar
  9. 9.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733–3737.CrossRefPubMedGoogle Scholar
  10. 10.
    Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432:922–924.CrossRefPubMedGoogle Scholar
  12. 12.
    Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473–477.CrossRefPubMedGoogle Scholar
  13. 13.
    De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997–1004.CrossRefPubMedGoogle Scholar
  14. 14.
    Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994;21:1109–1112.CrossRefPubMedGoogle Scholar
  15. 15.
    Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002;117:755–758.CrossRefPubMedGoogle Scholar
  16. 16.
    Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997;98:850–855.CrossRefPubMedGoogle Scholar
  17. 17.
    Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon alfa-2a and ribavirin for the treatment of hepatitis C in patients with thalassaemia. Haematologica 2008;93:1247–1251.CrossRefPubMedGoogle Scholar
  18. 18.
    Sood A, Midha V, Hissar S, et al. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol 2008;23:203–207.CrossRefPubMedGoogle Scholar
  19. 19.
    Tover JL, Buti M, Segarra A, Majo J, Esteban R. De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol 2008;40:539–541.CrossRefGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2010

Authors and Affiliations

  • Ajit Sood
    • 1
  • Praveen Sobti
    • 3
  • Vandana Midha
    • 2
  • Dinesh Singla
    • 1
  • Amarjeet Kaur
    • 4
  • Sandeep Kaushal
    • 5
  • Neena Sood
    • 4
  • Rasham Mittal
    • 1
  • Sandeep Puri
    • 2
  1. 1.Department of GastroenterologyDayanand Medical College and HospitalLudhianaIndia
  2. 2.Department of MedicineDayanand Medical College and HospitalLudhianaIndia
  3. 3.Department of PediatricsDayanand Medical College and HospitalLudhianaIndia
  4. 4.Department of PathologyDayanand Medical College and HospitalLudhianaIndia
  5. 5.Department of PharmacologyDayanand Medical College and HospitalLudhianaIndia

Personalised recommendations